Premarket Review and Safety of Nanodrugs
碩士 === 國立交通大學 === 科技法律研究所 === 99 === Nanomedicine is the sub-discipline of nanotechnology striving to use this technology to improve existing therapeutics or create new ones. By taking advantage of the development of chemistry, physics, materials science, engineering and biotechnology, the interd...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | zh-TW |
Published: |
2011
|
Online Access: | http://ndltd.ncl.edu.tw/handle/79010899030226322976 |
id |
ndltd-TW-099NCTU5705071 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-099NCTU57050712017-05-17T04:27:45Z http://ndltd.ncl.edu.tw/handle/79010899030226322976 Premarket Review and Safety of Nanodrugs 奈米藥品上市管制與藥品安全論 Chen, Peng-Yuan 陳鵬元 碩士 國立交通大學 科技法律研究所 99 Nanomedicine is the sub-discipline of nanotechnology striving to use this technology to improve existing therapeutics or create new ones. By taking advantage of the development of chemistry, physics, materials science, engineering and biotechnology, the interdisciplinary integration of nanotechnology promotes the research and commodification of medicine and brings significant change in medication. In other words, Nanotechnologies are the extensions of existing therapies and products that are already regulated: drugs, devices, and biologics, as well as combination products. Because this raises the pressing question of whether existing oversight frameworks and regulatory approaches are adequate and appropriate for nanomedicine, this article explored the regulations in U.S. and Taiwan to review the derived problems of nanodrugs. Further, due to lack of fundamental research of nanotoxicology and mature detecting and analyzing technique, nanomaterials are criticized to pose a great potential of risk of harm for human with a high degree of uncertainty. In such status of “non liquet,” this article tried to exploring the so called “safety” of drugs by comparing the concepts of safety in premarket approval of drugs, the design defect in product liability in U.S. and the implied concept in Drug Hazard Relief Act in Taiwan, to seek a balance for the safety of patients and new drug development in Taiwan. Chen, Chih-Hsiung 陳鋕雄 2011 學位論文 ; thesis 136 zh-TW |
collection |
NDLTD |
language |
zh-TW |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 國立交通大學 === 科技法律研究所 === 99 === Nanomedicine is the sub-discipline of nanotechnology striving to use this technology to improve existing therapeutics or create new ones. By taking advantage of the development of chemistry, physics, materials science, engineering and biotechnology, the interdisciplinary integration of nanotechnology promotes the research and commodification of medicine and brings significant change in medication. In other words, Nanotechnologies are the extensions of existing therapies and products that are already regulated: drugs, devices, and biologics, as well as combination products. Because this raises the pressing question of whether existing oversight frameworks and regulatory approaches are adequate and appropriate for nanomedicine, this article explored the regulations in U.S. and Taiwan to review the derived problems of nanodrugs.
Further, due to lack of fundamental research of nanotoxicology and mature detecting and analyzing technique, nanomaterials are criticized to pose a great potential of risk of harm for human with a high degree of uncertainty. In such status of “non liquet,” this article tried to exploring the so called “safety” of drugs by comparing the concepts of safety in premarket approval of drugs, the design defect in product liability in U.S. and the implied concept in Drug Hazard Relief Act in Taiwan, to seek a balance for the safety of patients and new drug development in Taiwan.
|
author2 |
Chen, Chih-Hsiung |
author_facet |
Chen, Chih-Hsiung Chen, Peng-Yuan 陳鵬元 |
author |
Chen, Peng-Yuan 陳鵬元 |
spellingShingle |
Chen, Peng-Yuan 陳鵬元 Premarket Review and Safety of Nanodrugs |
author_sort |
Chen, Peng-Yuan |
title |
Premarket Review and Safety of Nanodrugs |
title_short |
Premarket Review and Safety of Nanodrugs |
title_full |
Premarket Review and Safety of Nanodrugs |
title_fullStr |
Premarket Review and Safety of Nanodrugs |
title_full_unstemmed |
Premarket Review and Safety of Nanodrugs |
title_sort |
premarket review and safety of nanodrugs |
publishDate |
2011 |
url |
http://ndltd.ncl.edu.tw/handle/79010899030226322976 |
work_keys_str_mv |
AT chenpengyuan premarketreviewandsafetyofnanodrugs AT chénpéngyuán premarketreviewandsafetyofnanodrugs AT chenpengyuan nàimǐyàopǐnshàngshìguǎnzhìyǔyàopǐnānquánlùn AT chénpéngyuán nàimǐyàopǐnshàngshìguǎnzhìyǔyàopǐnānquánlùn |
_version_ |
1718449072028778496 |